Immunologic responses to sublingual allergen immunotherapy

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 71-86

  Akdis, Mübeccel ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

BLOOD; DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; METABOLISM; REGULATORY T LYMPHOCYTE; REVIEW; SUBLINGUAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; DESENSITIZATION, IMMUNOLOGIC; HISTAMINE; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLAMMATION; T-LYMPHOCYTES, REGULATORY;

EID: 58149468461     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (113)

1. Akdis CA. Mechanisms of allergic disease. Curr Opin Immunol 2006; 18(6): 718-726.
2. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113(3): 395-400.
3. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6(10): 761-771.
4. Akdis CA, Blaser K, Akdis M. Apoptosis in tissue inflammation and allergic disease. Curr Opin Immunol 2004; 16(6): 717-723.
5. Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006; 18(6): 738-744.
6. Trautmann A, Schmid-Grendelmeier P, Krüger K, et al. T cells and eosinophils cooperate in the induction of bronchial epithelial apoptosis in asthma. J Allergy Clin Immunol 2002; 109: 329-337.
7. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119(4): 780-791.
8. Black J. The oral administration of pollen. J Lab Clin Med 1927; 12: 1156.
9. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111(3): 437-448.
10. Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma-a double-blind study. J Investig Allergol Clin Immunol 1992; 2(2): 59-67.
11. Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991; 87(3): 721-728.
12. Malling HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002; 2(6): 523-531.
13. Passalacqua G, Guerra L, Pasquali M, et al. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004; 93(1): 3-12.
14. Passalacqua G, Guerra L, Compalati E, et al. New insights in sublingual immunotherapy. Curr Allergy Asthma Rep 2006; 6(5): 407-412.
15. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60(1): 4-12.
16. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136(3): 287-294.
17. Arikan C, Bahceciler NN, Deniz G, et al. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004; 34(3): 398-405.
18. Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14(3): 216-221.
19. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118(2): 434-440.
20. Razafindratsita A, Saint-Lu N, Mascarell L, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120(2): 278-285.
21. Passalacqua G, Albano M, Fregonese L, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation inmite-induced rhinoconjunctivitis. Lancet 1998; 351: 629-632.
22. Allam JP, Niederhagen B, Bucheler M, et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61(2): 166-172.
23. Samsom JN, van Berkel LA, van Helvoort JM, et al. Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells. J Immunol 2005; 174(9): 5279-5287.
24. vanHelvoort JM, SamsomJN, Chantry D, et al. Preferential expression of IgG2b in nose draining cervical lymph nodes and its putative role in mucosal tolerance induction. Allergy 2004; 59(11): 1211-1218.
25. Moingeon P, Batard T, Fadel R, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61(2): 151-165.
26. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergeninduced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61(10): 1184-1190.
27. Kinaciyan T, Jahn-Schmid B, Radakovics A, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 2007; 119: 937-943.
28. Woo HY, Kim YS, Kang NI, et al. Mechanism for acute oral desensitization to antibiotics. Allergy 2006; 61(8): 954-958.
29. Eberlein-Konig B, Ullmann S, Thomas P, et al. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995; 25(8): 704-712.
30. Jutel M, Muller UR, Fricker M, et al. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996; 26(10): 1112-1118.
31. Plewako H, Wosinska K, Arvidsson M, et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006; 141(4): 346-353.
32. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98: 1676-1683.
33. Akdis CA, Blesken T, Akdis M, et al. Role of IL-10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106.
34. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-b cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-1214.
35. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116(5): 961-968.
36. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-1214.
37. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111(6): 1255-1261.
38. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363(9409): 608-615.
39. Schmidt-Weber CB, Blaser K. Regulation and role of transforming growth factor-beta in immune tolerance induction and inflammation. Curr Opin Immunol 2004; 16(6): 709-716.
40. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199(11): 1567-1575.
41. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120(3): 707-713.
42. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow’s milk allergy. J Exp Med 2004; 199(12): 1679-1688.
43. Cavani A, Nasorri F, Ottaviani C, et al. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003; 171(11): 5760-5768.
44. Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004; 101(12): 4228-4233.
45. Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005; 116(5): 949-959.
46. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117(1): 176-183.
47. Taylor A, Akdis M, Joss A, et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 2007; 120(1): 76-83.
48. Van Ree R, Van Leeuwen WA, Dieges PH, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27(1): 68-74.
49. Gleich GJ, Zimmermann EM, Henderson LL, et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982; 70(4): 261-271.
50. Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82(3 pt 1): 439-446.
51. Golden DB, Meyers DA, Kagey-Sobotka A, et al. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982; 69(6): 489-493.
52. Müller UR, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989; 44: 412-418.
53. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116(3): 608-613.
54. Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005; 116(2): 347-354.
55. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120(3): 688-695.
56. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4(4): 313-318.
57. Till SJ, Francis JN, Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113(6): 1025-1034.
58. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1): 134-140.
59. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105(1): 9-19.
60. Poirier MP, Ahlstedt S, Ford J, et al. Use of thiocyanate elution to estimate relative avidity of allergen specific IgE antibodies. Allergy Asthma Proc 1997; 18(6): 359-362.
61. Rossi RE, Monasterolo G, Coco G, et al. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007; 25(5): 957-964.
62. Sonoda E, Matsumoto R, Hitoshi Y, et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 1989; 170: 1415-1420.
63. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6(10): 741-750.
64. Pierkes M, Bellinghausen I, Hultsch T, et al. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999; 103(2 pt 1): 326-332.
65. Marshall JS, Leal-Berumen I, Nielsen L, et al. Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 1996; 97: 1122-1128.
66. Schandane L, Alonso-Vega C, Willems F, et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994; 152: 4368-4374.
67. Palaniyandi SS, Watanabe K, Ma M, et al. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur J Immunol 2004; 34(12): 3508-3515.
68. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82(3 pt 1): 470-480.
69. Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990; 86(5): 706-713.
70. Hakansson L, Heinrich C, Rak S, et al. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997; 99(4): 551-562.
71. Creticos PS, Adkinson NF Jr., Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985; 76(6): 2247-2253.
72. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115(6): 1184-1188.
73. Crameri R, Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006; 18(6): 761-768.
74. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22: 175-178.
75. Larche M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006; 18(6): 745-750.
76. Kussebi F, Karamloo F, Rhyner C, et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 115: 323-329.
77. Karamloo F, Schmid-Grendelmeier P, Kussebi F, et al. Prevention of allergy by a recombinant multiallergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005; 35(11): 3268-3276.
78. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101(suppl 2): 14677-4682.
79. Johansen P, Haffner AC, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005; 35(2): 568-574.
80. Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113(6): 1144-1151.
81. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-1455.
82. Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117(6): 1470-1476.
83. Zhu D, Kepley CL, Zhang M, et al. Anovel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8(5): 518-521.
84. Van Overtvelt L, Lombardi V, Razafindratsita A, et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2007; 145(2): 152-162.
85. Rhyner C, Kundig T, Akdis CA, et al. Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 2007; 35(pt 4): 833-834.
86. Jutel M, Watanabe T, Akdis M, et al. Immune regulation by histamine. Curr Opin Immunol 2002; 14(6): 735-740.
87. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533(1-3): 69-76.
88. Bryce PJ, Mathias CB, Harrison KL, et al. The H1 histamine receptor regulates allergic lung responses. J Clin Invest 2006; 116(6): 1624-1632.
89. Seligmann BE, Fletcher MP, Gallin JI. Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes. J Immunol 1983; 130(4): 1902-1909.
90. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. J Clin Invest 1993; 92(1): 281-287.
91. Meretey K, Falus A, Taga T, et al. Histamine influences the expression of the interleukin-6 receptor on human lymphoid, monocytoid and hepatoma cell lines. Agents Actions 1991; 33(1-2): 189-191.
92. Jeannin P, Delneste Y, Gosset P, et al. Histamine induces interleukin-8 secretion by endothelial cells. Blood 1994; 84(7): 2229-2233.
93. Bayram H, Devalia JL, Khair OA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol 1999; 104(1): 93-99.
94. Fujikura T, Shimosawa T, Yakuo I. Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa. J Allergy Clin Immunol 2001; 107(1): 123-128.
95. Elenkov IJ, Webster E, Papanicolaou DA, et al. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998; 161(5): 2586-2593.
96. van der Pouw Kraan TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998; 102(10): 1866-1873.
97. Takahashi HK, Iwagaki H, Mori S, et al. Histamine inhibits lipopolysaccharide-induced interleukin (IL)-18 production in human monocytes. Clin Immunol 2004; 112(1): 30-34.
98. Takahashi HK, Morichika T, Iwagaki H, et al. Histamine downregulates CD14 expression via H2 receptors on human monocytes. Clin Immunol 2003; 108(3): 274-281.
99. Morichika T, Takahashi HK, Iwagaki H, et al. Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1- and B7.1-dependent manner. J Pharmacol Exp Ther 2003; 304(2): 624-633.
100. Mazzoni A, Young HA, Spitzer JH, et al. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108(12): 1865-1873.
101. Ohtani T, Aiba S, Mizuashi M, et al. H1 and H2 histamine receptors are absent on Langerhans cells and present on dermal dendritic cells. J Invest Dermatol 2003; 121(5): 1073-1079.
102. Akdis M, Trautmann A, Klunker S, et al. T helper (Th) 2 predominance in atopic disease is due to preferential apoptosis of circulating memory/effector Th1 cells. Faseb J 2003; 17: 1026-1035.
103. Soga F, Katoh N, Kishimoto S. Histamine prevents apoptosis in human monocytes. Clin Exp Allergy 2007; 37(3): 323-330.
104. Gantner F, Sakai K, Tusche MW, et al. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 2002; 303(1): 300-307.
105. Sirois J, Menard G, Moses AS, et al. Importance of histamine in the cytokine network in the lung through H2 and H3 receptors: stimulation of IL-10 production. J Immunol 2000; 164(6): 2964-2970.
106. Benovic J. Novel b2-adrenergic receptor signaling pathways. J Allergy Clin Immunol 2002; 110: 229-235.
107. Szeberenyi JB, Pallinger E, Zsinko M, et al. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 2001; 76(3): 175-182.
108. Idzko M, la Sala A, Ferrari D, et al. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002; 109(5): 839-846.
109. Gutzmer R, Langer K, Lisewski M, et al. Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002; 109(3): 524-531.
110. Caron G, Delneste Y, Roelandts E, et al. Histamine polarizes human dendritic cells into Th2 cellpromoting effector dendritic cells. J Immunol 2001; 167(7): 3682-3686.
111. Caron G, Delneste Y, Roelandts E, et al. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J Immunol 2001; 166(10): 6000-6006.
112. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413(6854): 420-425.
113. Osna N, Elliott K, Khan MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001; 1(1): 85-96.